ASCO 2023 | Belzutifan as a non-invasive treatment option for VHL-associated tumors

Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, dsicusses the use of belzutifan in VHL-associated tumors. Belzutifan shows higher efficacy and better safety compared to VEGF TKIs like sunitinib and pazopanib in VHL-associated tumors. Real-world evidence shows belzutifan is well-tolerated, with minimal side effects such as anemia and fatigue. belzutifan can be a viable systemic alternative, potentially reducing the need for surgery in these patients and improving their quality of life. During the median eight-month follow-up of the real-world study on belzutifan in VHL-associated tumors, none of the patients required surgery, indicating its potential as an effective and non-invasive treatment option. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.